BHV-2100 is under clinical development by Biohaven and currently in Phase II for Neuropathic Pain (Neuralgia).

ANP-390 is under clinical development by AlphaNavi Pharma and currently in Phase I for Peripheral Neuropathic Pain.

New Delhi: Rahi Sarnobat recalls that autumn day of 2022 with clarity. Indian shooters, following a medalless Tokyo Olympics campaign a year before, were gearing up for the Cairo World ...

On Friday, Bernstein SocGen Group adjusted its outlook on Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ: VRTX), a $102 billion biotechnology giant, reducing the price target from the ...

I Was Diagnosed With Dyslexia: Junaid Khan Opens Up On Learning Disability He Was Diagnosed With A The Age of 6 It's Been Quite Tough: Gurmeet Choudhry Has Not Eaten Roti and Rice For More Than A Year ...

Results of a small study suggest similar pathophysiology of cognitive dysfunction and neuropathic pain in patients with long COVID. Among patients with long COVID, approximately 20% were found to have ...